Alkermes reports Q3 GAAP loss of $0.39/share; plans to separate oncology business

Alkermes plc.

Q3 total revenues $252.4M; net loss $64.0M; GAAP EPS -$0.39, non-GAAP EPS $0.02.
Proprietary product net sales $199.4M: VIVITROL $96.5M (+9% YoY), ARISTADA $75.7M (+10%), LYBALVI $27.1M.
Board approved exploration of separating oncology business into independent public company; expected completion H2 2023.
Updated FY2022 guidance: total revenue $1.07B-$1.12B, non-GAAP EPS $0.15-$0.33; LYBALVI outlook raised to $88-$95M.
One-time AMPYRA royalty reversal of ~$21.5M due to arbitration award.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alkermes plc. reported the third quarter of 2022 results: revenue $252.4 million, net income $64.0 million, EPS $0.39.

Period: the third quarter of 2022
Revenue: $252.4 million
Net income: $64.0 million
EPS: $0.39
Result: reported results

Exact text from the filing

— Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alkermes plc. reported the year ending December 31, 2022 results: revenue $1,070 – $1,120. Guidance raised.

Period: the year ending December 31, 2022
Revenue: $1,070 – $1,120
Guidance: raised
Result: guidance update

Exact text from the filing

to GAAP, except as otherwise noted. In millions (except per share amounts) Current 2022 Expectation (Provided 11/2/22) Prior 2022 Expectation (Provided 7/27/22) Total Revenue $1,070 – $1,120 $1,050 – $1,120 VIVITROL Net Sales $370 – $380 $365 – $385 ARISTADA Net Sales $300 – $310 $295 – $315 LYBALVI Net Sales $88 – $

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0000950170-22-020969

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.